入境高风险特殊物品全链条管理模式研究

Study on whole chain management mode of imported high-risk special products

在生物医药行业快速发展、特殊物品进出口量剧增和全球新冠肺炎疫情形势复杂的背景下,文章详细介绍了我国和美国的进出口特殊物品监管机制,并进行了对比,从而分析国内特殊物品监管存在的立法漏洞、信息孤岛、监管盲区、监管空白和检测困境等问题,据此提出建立入境高风险特殊物品全链条管理模式的建议。在保障入境高风险特殊物品安全监管的前提下,探索推动设立与国内外生物安全形势和特殊物品监管需求相适应的法律法规;联合多部门优化和完善特殊物品入境后的监管机制,切实解决特殊物品入境检测困境和监管盲区等难题;提升通关便利化水平,使入境高风险特殊物品监管作业更加完善、高效,以科学的监管扶持生物医药产业做大做强。

Under the background of the rapid development of the biopharmaceutical industry and the sharp increasing import and export volume of special products with the complex situation of the pandemic of COVID-19,this article introduces and compares the supervision mechanism of import and export of special products in China and the United States in detail. It analyzes the legislative loopholes,information silos,regulatory blind spots,regulatory gaps and detection difficulties in the supervision of special products in China. Accordingly,we propose to establish a whole-chain management model for high-risk special inbound products in China. On the premise of ensuring the safety supervision of high-risk special products,we suggest to explore and promote the establishment of laws that are compatible with the domestic and international biosecurity situation and the supervision needs of special products. In addition to this,we also recommend to cooperate with multiple departments to optimize and improve the supervision mechanism of special products after the entry. With above measures we can effectively solve the difficulties of entry inspection of special products and supervision blind spots,and improve the level of customs clearance facilitation,thus making the supervision of the entry of highrisk special products more complete and efficient to support the biopharmaceutical industry become bigger and stronger with scientific regulation.